Korea South
EpiBiotech, established in 2015, stands out in the Korean market as a pioneering research and development company focused on innovative hair loss treatments. Unique in its field, EpiBiotech is exploring breakthroughs leveraging its proprietary research technology.
The company distinguishes itself with its GMP-approved facilities and robust pipeline targeting new solutions to an enduring issue plaguing many. Unlike current synthetic drugs that require daily dosing and can have undesirable side effects, EpiBiotech is venturing into the promising realms of antibody treatment and cell therapy.
Headquartered in South Korea, the company completed its last significant capital raise—a Series B round of KRW10.20 billion—on May 11, 2021. The funding round attracted investment from notable firms such as Korea Investment Partners, Korea Development Bank, E&Investment, IMM Investment, and DAOL Investment & Securities. This investment not only underscores confidence in EpiBiotech's technology and market potential but also provides a solid foundation for advancing its research objectives.
